ExpreS2ion Biotechnologies
ExpreS2ion Biotechnologies is a platform-based biotech company with its own research & development (R&D).
They use their proprietary manufacturing technology platform, ExpreS2™, to develop a pipeline of immunotherapeutic cancer treatments (initially targeting breast cancer) and preventive vaccines against infectious diseases (including malaria, influenza, and Nipah virus). In addition, their ExpreS2 platform is used to support customers who require recombinant proteins produced in the ExpreS2 system.
ExpreS2ion is part of DTU Science Park’s deep tech community and they have their own laboratories in Hørsholm which they use for cell culture development, as well as purification and process development.
Right now, their breast cancer vaccine project, ES2B-C001, is a key focus and is currently being investigated in a clinical Phase 1 study in Austria.
Phanofi
Phanofi develops next-generation optical transceiver modules for data centers.
These modules connect the electrical signals inside servers to high-speed optical links between servers, enabling faster and more efficient data transmission.
The company focuses on increasing bandwidth while significantly improving energy efficiency. Lower energy per transmitted bit reduces the overall power consumption and cost of computation in modern data centers – an increasingly important factor as AI and cloud workloads continue to scale.
Phanofi is part of DTU Science Park’s deep tech community. The team has its office in Lyngby at DTU campus and operates a photonics laboratory. In the lab, they characterize and test optical prototypes using high-speed measurements and system validation. The close proximity between office and lab enables fast iteration between design and experimental testing.
The location at DTU Science Park also provides access to meeting facilities, collaboration opportunities, and close interaction with DTU researchers and students.
Right now, Phanofi is testing its first fabricated prototypes while refining its design and supply chain, with the goal of bringing its first commercial product, Terra Sigma, a 1.6T pluggable optical transceiver module, to market.
TOOsonix
TOOsonix develops and produces medical therapeutic devices based on focused ultrasound technology.
Focused ultrasound is a non-invasive treatment modality that offers high efficacy while minimizing treatment pain, eliminating the need for post-treatment aftercare, and typically avoiding long-term side effects.
The company’s devices are designed for dermatological therapies, including treatment of basal cell skin cancers and pre-cancerous actinic keratoses, as well as common benign skin conditions such as seborrheic keratosis, cherry angiomas, and sebaceous hyperplasia. Most treatments are completed in a single session, lasting around one minute per treatment area and usually without the need for anesthesia.
TOOsonix is also part of DTU Science Park’s deep tech community and is located in Hørsholm. The company operates its own facilities for mechanical, electronic, and ultrasound development.
In 2024, TOOsonix obtained MDR Class IIa CE marking for its main medical device. The company is now focusing on operational optimization and expanding its distribution network across Europe and into new international markets.
Valinor
Valinor ApS is developing a fundamentally new approach to cancer treatment.
The company’s patented technology targets cancer cells from the inside by leveraging one of the defining features of cancer: the accumulation of DNA mutations that distinguish cancer cells from healthy cells.
Using highly precise DNA “scissors” based on CRISPR technology, Valinor’s treatment introduces DNA breaks only at cancer-specific mutations, leaving healthy cells unharmed. The therapy is tailored to each individual patient using genomic DNA sequencing, making it possible to design treatments based on the unique mutation profile of a person’s cancer. Because the approach targets mutations rather than a specific tumor type, the technology is potentially applicable across all cancer types.
Valinor operates laboratory and office facilities at DTU Science Park in Lyngby. The company also benefits from shared services and facilities at the science park, including reception, meeting rooms, mail and printing services, and canteen.
Valinor has already demonstrated strong proof-of-concept results in both laboratory cell cultures and mouse tumor models. The team is now working on establishing the production pipeline for its customized therapeutic drug particles while preparing for safety pharmacology studies.
